Optimal biological dose: a systematic review in cancer phase I clinical trials - Archive ouverte HAL Access content directly
Journal Articles BMC Cancer Year : 2021

Optimal biological dose: a systematic review in cancer phase I clinical trials

(1) , (2) , (1) , (2) , (1, 3)
1
2
3

Abstract

Background: Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immunotherapies, the concept of optimal biological dose (OBD) was subsequently introduced to account for efficacy in addition to toxicity. The objective was therefore to provide an overview of published phase 1 cancer clinical trials relying on the concept of OBD. Methods: We performed a systematic review through a computerized search of the MEDLINE database to identify early phase cancer clinical trials that relied on OBD. Relevant publications were selected based on a two-step process by two independent readers. Relevant information (phase, type of therapeutic agents, objectives, endpoints and dose-finding design) were collected. Results: We retrieved 37 articles. OBD was clearly mentioned as a trial objective (primary or secondary) for 22 articles and was traditionally defined as the smallest dose maximizing an efficacy criterion such as biological target: biological response, immune cells count for immunotherapies, or biological cell count for targeted therapies. Most trials considered a binary toxicity endpoint defined in terms of the proportion of patients who experienced a doselimiting toxicity. Only two articles relied on an adaptive dose escalation design. Conclusions: In practice, OBD should be a primary objective for the assessment of the recommended phase 2 dose (RP2D) for a targeted therapy or immunotherapy phase I cancer trial. Dose escalation designs have to be adapted accordingly to account for both efficacy and toxicity.
Fichier principal
Vignette du fichier
s12885-021-07782-z.pdf (692.62 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03217931 , version 1 (05-05-2021)

Identifiers

Cite

J Fraisse, D Dinart, D Tosi, C Bellera, C Mollevi. Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer, 2021, 21 (1), pp.60. ⟨10.1186/s12885-021-07782-z⟩. ⟨inserm-03217931⟩
44 View
67 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More